Targeted Therapy of the Epidermal Growth Factor Receptor in the Treatment of Pancreatic Cancer
| Autor: | Steffen Heeger |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
medicine.medical_specialty Cetuximab biology business.industry medicine.medical_treatment Cancer medicine.disease Targeted therapy Internal medicine Pancreatic cancer medicine biology.protein Adenocarcinoma of the lung CA19-9 Erlotinib Epidermal growth factor receptor business medicine.drug |
| Zdroj: | Pancreatic Cancer ISBN: 9783540712664 |
| Popis: | The epidermal growth factor receptor (EGFR)-mediated pathway is one of the most promising targets for the development of new strategies in anticancer treatments. The so-called "small molecule" tyrosine kinase inhibitor erlotinib has gained marketing authorization in the United States for advanced adenocarcinoma of the lung and for pancreatic cancer, whereas the antibody cetuximab is registered for metastatic colorectal cancer and cancers of the head and neck. Ongoing studies are evaluating the impact of EGFR-targeting therapy in the treatment of locally advanced and metastatic pancreatic cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|